Aclaris Therapeutics

Positives: the Biosion license secured two late‑preclinical/early‑clinical antibody assets across TSLP and IL‑4/13 biology with global ex‑Greater China rights. The company monetized non‑core royalty streams (Lilly OLUMIANT) to OMERS to add non‑dilutive cash, and it pragmatically pivoted ATI‑2138 from AD to lichen planus where competition is lower.

Negatives: the 2023 discontinuation of zunsemetinib after a Phase 2b failure and the historical discontinuation of earlier commercial efforts highlight execution risk.

The March 2026 ATM raise was timely but contributes to substantial dilution, and the Biosion warrants (14.3 million shares, 3.0 million unexercised as of March 31, 2026) further dilute existing holders. Score is middling pending demonstration that recent R&D spend translates into clear clinical differentiation and partnering traction.